GB2579253A - Antibacterial antisense agents - Google Patents

Antibacterial antisense agents Download PDF

Info

Publication number
GB2579253A
GB2579253A GB1819399.5A GB201819399A GB2579253A GB 2579253 A GB2579253 A GB 2579253A GB 201819399 A GB201819399 A GB 201819399A GB 2579253 A GB2579253 A GB 2579253A
Authority
GB
United Kingdom
Prior art keywords
cat
compound according
group
antisense
cca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1819399.5A
Other languages
English (en)
Other versions
GB201819399D0 (en
Inventor
Quibell Martin
Shulz-Utermoehl Timothy
Murray Fraser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pedanius Therapeutics Ltd
Original Assignee
Pedanius Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedanius Therapeutics Ltd filed Critical Pedanius Therapeutics Ltd
Priority to GB1819399.5A priority Critical patent/GB2579253A/en
Publication of GB201819399D0 publication Critical patent/GB201819399D0/en
Priority to JP2021531369A priority patent/JP2022510346A/ja
Priority to AU2019386368A priority patent/AU2019386368A1/en
Priority to PCT/GB2019/053354 priority patent/WO2020109792A1/en
Priority to US17/296,748 priority patent/US20220106595A1/en
Priority to EP19816851.0A priority patent/EP3887520A1/en
Priority to CA3121064A priority patent/CA3121064A1/en
Priority to KR1020217019995A priority patent/KR20210098493A/ko
Priority to CN201980090482.5A priority patent/CN113366107A/zh
Publication of GB2579253A publication Critical patent/GB2579253A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1819399.5A 2018-11-28 2018-11-28 Antibacterial antisense agents Withdrawn GB2579253A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB1819399.5A GB2579253A (en) 2018-11-28 2018-11-28 Antibacterial antisense agents
CN201980090482.5A CN113366107A (zh) 2018-11-28 2019-11-27 抗细菌反义药剂
US17/296,748 US20220106595A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents
AU2019386368A AU2019386368A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents
PCT/GB2019/053354 WO2020109792A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents
JP2021531369A JP2022510346A (ja) 2018-11-28 2019-11-27 抗菌アンチセンス剤
EP19816851.0A EP3887520A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents
CA3121064A CA3121064A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents
KR1020217019995A KR20210098493A (ko) 2018-11-28 2019-11-27 항세균성 안티센스제

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1819399.5A GB2579253A (en) 2018-11-28 2018-11-28 Antibacterial antisense agents

Publications (2)

Publication Number Publication Date
GB201819399D0 GB201819399D0 (en) 2019-01-09
GB2579253A true GB2579253A (en) 2020-06-17

Family

ID=65024582

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1819399.5A Withdrawn GB2579253A (en) 2018-11-28 2018-11-28 Antibacterial antisense agents

Country Status (9)

Country Link
US (1) US20220106595A1 (cg-RX-API-DMAC7.html)
EP (1) EP3887520A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022510346A (cg-RX-API-DMAC7.html)
KR (1) KR20210098493A (cg-RX-API-DMAC7.html)
CN (1) CN113366107A (cg-RX-API-DMAC7.html)
AU (1) AU2019386368A1 (cg-RX-API-DMAC7.html)
CA (1) CA3121064A1 (cg-RX-API-DMAC7.html)
GB (1) GB2579253A (cg-RX-API-DMAC7.html)
WO (1) WO2020109792A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2020665A (en) * 1978-03-31 1979-11-21 Hirai Y Acyl-N-acetylmuramylpeptide- antigen conjugate
WO2014205451A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2018165564A1 (en) * 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
EP0541486A1 (de) 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
WO2006104530A1 (en) * 2005-03-28 2006-10-05 Cell Works Therapeutics, Inc. Therapeutics targeted to renal cells
WO2014002039A1 (en) 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
EP2845607A1 (en) 2013-09-09 2015-03-11 University of Vienna Antisense oligonucleotides with improved pharmacokinetic properties
US9790495B2 (en) 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
WO2016108930A2 (en) 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
JPWO2017010575A1 (ja) * 2015-07-16 2018-04-26 協和発酵キリン株式会社 β2GPI遺伝子発現抑制核酸複合体
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2020665A (en) * 1978-03-31 1979-11-21 Hirai Y Acyl-N-acetylmuramylpeptide- antigen conjugate
WO2014205451A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2018165564A1 (en) * 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds

Also Published As

Publication number Publication date
WO2020109792A1 (en) 2020-06-04
JP2022510346A (ja) 2022-01-26
AU2019386368A1 (en) 2021-07-01
GB201819399D0 (en) 2019-01-09
KR20210098493A (ko) 2021-08-10
CA3121064A1 (en) 2020-06-04
EP3887520A1 (en) 2021-10-06
US20220106595A1 (en) 2022-04-07
CN113366107A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
CN108715594B (zh) 微小rna抑制剂
TW201728579A (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
IL229387A (en) Spiro-oxindole antagonists of mdm2
US20240165245A1 (en) Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
EA031110B1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
CN115028648B (zh) 三并环化合物及其药物组合物和应用
CA2819944A1 (en) Modified single-stranded polynucleotide
EP3112372B1 (en) Pantothenate derivatives for the treatment of neurologic disorders
CN102603871B (zh) 新型硫链丝菌素类似物及其制法和用途
CN109477090A (zh) 微小rna-143衍生物
CA2954653C (en) N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
US11279733B2 (en) Peptide antibiotics
WO2023131677A1 (en) Compounds containing a hydroxyphenyl moiety and their use
Kandasamy et al. Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations
EP3724333A2 (en) Oligonucleotides for modulating fndc3b expression
KR101646309B1 (ko) 장 면역활성 조절용 조성물 및 이의 용도
JP2023544643A (ja) バクチオ-ル誘導体、その薬学的に許容される塩及びその調製方法並びに用途
CN121889397A (zh) 化合物或其盐及其制造方法、包含化合物或其盐的药物组合物及其制造方法
EP2440533B1 (en) Guanine riboswitch binding compounds and their use as antibiotics
US20220106595A1 (en) Antibacterial antisense agents
JP2018536426A (ja) ミクロモノスポラ・カルボナセア変種アウランティアカ(Micromonospora carbonacea var aurantiaca)におけるエベルニノマイシンアナログの生合成
KR20100102130A (ko) 신규한 아미노글리코시드 항생제, 그것의 제조 방법 및 약제학적 용도
TW201336860A (zh) 針對acsl1之反意寡核苷酸
EP2651878A1 (en) Cyclohexane compounds and their use as antibiotics
EP3634974A1 (en) Tunicamycin analogues

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)